Royalty Pharma plc (NASDAQ:RPRX) currently has a daily average trading volume of 4.63M but it saw 3331018 shares traded in last market. With a market cap of 18.62B USD, the company’s current market price of $33.12 came rising about 2.57 while comparing to the previous closing price of $32.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $34.20 and as low as $24.05.
Taking a look at 20-day trading activity of Royalty Pharma plc (RPRX) gives us an average price of $32.60, while its current price level is -3.16% below from 52-week high level whereas it is 37.71% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $32.43 while that of 200 days or SMA-200 reads an average of $29.29. A closer look into the stock’s movement over the week reveals that its volatility is standing at 2.53% during that period while stretching the period over a month that decreases to 2.25%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 55.26 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the UBS which downgraded the stock as “Neutral” in its note to investors issued on June 03, 2024, recommending a price target of $28 for it. Scotiabank issued its recommendations for the stock as it initiated the price target for the stock is $53.
Over the week, RPRX’s stock price is moving 0.06% up while it is 2.06% when we observe its performance for the past one month. Year-to-date it is 29.83% up and over the past year, the stock is showing an upside performance of 16.70%.
Currently, Royalty Pharma plc’s total number of outstanding shares is 425.59M with 8.72% of that held by the insiders while 82.27% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 8.21% and return on equity (ROE) at 16.57%. It has a price to earnings ratio (P/E ratio) of 13.51 while having a 6.46 of forward P/E ratio. Stock’s beta reads 0.47. Stock has a price to book (P/B) ratio of 2.11 while price to sale or P/S ratio amounts to 8.23. Its return on asset (ROA) is 6.48% on average.
